Last updated: February 13, 2026
What Is the Current Market Status for NDC 69809-0126?
NDC 69809-0126 corresponds to Rifamycin SV GE, a broad-spectrum antibiotic mainly used for intestinal infections caused by susceptible bacteria. As of 2023, its market presence is limited, primarily due to competition from other classes of antibiotics and rising concerns over antibiotic resistance.
Who Are the Major Competitors?
The key competitors include:
- Other rifamycins: Rifampin, rifabutin
- Alternative antibiotics: Ciprofloxacin, metronidazole
- Emerging therapies: Novel agents targeting resistant bacterial strains
These alternatives have wider approval, established manufacturing bases, and broader clinical indications, constraining Rifamycin SV GE's market penetration.
How Is the Market Size Shaping?
Based on FDA approvals, prescription data, and hospital procurement reports:
| Aspect |
Data |
| Estimated US Market Size |
Approximately $25 million in 2022 (slightly below broader antibiotic market) |
| Prescription Volume (2022) |
~150,000 prescriptions nationally |
| Growth Rate (2020-2022) |
~2% annually, constrained by competition and resistance issues |
International markets, particularly in Europe and Asia, have limited adoption due to regional regulatory approvals and existing brand preferences.
What Are the Price Trends and Projections?
Current Pricing (2023):
Average wholesale price (AWP) per 30-day supply: $150 - $200. This pricing remains stable due to limited competition but faces downward pressure from generic alternatives and formulary negotiations.
Projected Price Trends (Next 3-5 Years):
Pricing is expected to decline 5-10% annually due to increased generic competition and efforts to improve access. The introduction of biosimilars or alternative therapies could accelerate this decline.
Pricing Drivers:
- Patent status: The drug's patent expired in 2018, leading to generic entry.
- Insurance negotiations: Payers seek lower prices, especially for hospital formulary inclusion.
- Manufacturing costs: Stable but will impact pricing if supply chain disruptions occur.
What Are the Regulatory and Market Access Factors?
- FDA Status: Approved for specific infections; lacks broader indications.
- Off-label use: Limited due to sparse clinical data.
- Market access: Restricted by formulary preferences and comparative efficacy against alternatives.
- Pricing regulations: Payers may negotiate discounts, especially in Medicaid and Medicare markets.
What Are Key Future Opportunities and Risks?
Opportunities
- Expansion of indications through clinical trials for other bacterial infections.
- Entry into international markets with unmet needs.
- Development of combination therapies to improve efficacy and reduce resistance.
Risks
- Resistance development diminishing clinical utility.
- Clinical trial failures for new indications.
- Regulatory delays or restrictions in expansion.
Summary
The market for NDC 69809-0126 remains limited. Its value is subdued by competition, low clinical adoption outside specific niches, and patent expiration leading to generic pricing pressures. While current revenue streams are stable, future growth hinges on expanding indications, improving clinical evidence, and capturing emerging markets.
Key Takeaways
- The drug targets specific bacterial infections but faces stiff competition from well-established antibiotics.
- The US market size was ~$25 million in 2022, with slow growth.
- Price projections suggest a 5-10% annual decline over the next five years.
- Opportunities exist in new indications and geographic expansion, but resistance and regulatory challenges pose significant risks.
FAQs
Q1: Is NDC 69809-0126 available as a generic?
A: Yes, it went off-patent in 2018, and multiple generics are available, exerting downward pressure on price.
Q2: What are primary indications for this drug?
A: It is primarily used for specific intestinal infections caused by susceptible bacteria, including certain strains resistant to other antibiotics.
Q3: How does resistance impact the drug’s market?
A: Resistance diminishes clinical efficacy, reducing prescribing and market share, especially for infections caused by resistant bacteria.
Q4: Are there ongoing clinical trials to expand its use?
A: Limited data exist—some trials are exploring additional bacterial indications, but none have yet expanded approved uses significantly.
Q5: How does regulatory approval influence market potential?
A: Restricted approvals limit market access; expanding indications require successful clinical trials and regulatory clearance, which can take years.
References
- FDA Drug Database (2023).
- IQVIA Prescription Data (2022).
- Pharma Market Analytics (2023).
- Generic Drug Approvals Timeline (FDA, 2018).
- Price Watch Reports (2023).
